TY - JOUR

T1 - Predictors of accelerated FEV1 decline in adults with airflow limitation

T2 - Findings from the Health2006 cohort

AU - Baarnes, Camilla Boslev

AU - Thuesen, Betina H.

AU - Linneberg, Allan

AU - Ustrup, Amalie S.

AU - Pedersen, Signe Knag

AU - Ulrik, Charlotte Suppli

PY - 2019

Y1 - 2019

N2 - To investigate predictors of accelerated decline in forced expiratory volume in 1 s (FEV1) in individuals with preexisting airflow limitation (AL). Participants in the Health2006 baseline study aged ≥ 35 with FEV1/ forced vital capacity (FVC) < lower limit of normal (LLN) were invited for a 10-year follow-up. At both examinations, data were obtained on demographics, spirometry, fitness level, allergy, and exhaled nitric oxide. We used multiple regression modeling to predict the annual decline in FEV1, reported as regression coefficients (R) and 95% confidence intervals (CIs). A total of 123 (43% of those invited) participated in the follow-up examination, where more had exercise-induced dyspnea but fewer had asthma symptoms. Being female (R = −29.8 ml, CI: −39.7 to −19.8), diagnosed with asthma (R = −13.7, CI: −20.4 to −7.0) or atopic dermatitis (R = −29.0, CI: −39.7 to −18.4), and having current asthma symptoms or nightly respiratory symptoms (R = −22.1, CI: −31.9 to −12.4 and R = −14.3, CI: −19.9 to −8.7, respectively) were significantly associated with a steeper decline in FEV1. Although to a smaller extent, a steeper decline was also predicted by age, baseline FEV1, waist/hip-ratio, and number of pack-years smoked. In individuals with preexisting AL, being female and having ever or current respiratory symptoms were associated with an accelerated annual decline in FEV1.

AB - To investigate predictors of accelerated decline in forced expiratory volume in 1 s (FEV1) in individuals with preexisting airflow limitation (AL). Participants in the Health2006 baseline study aged ≥ 35 with FEV1/ forced vital capacity (FVC) < lower limit of normal (LLN) were invited for a 10-year follow-up. At both examinations, data were obtained on demographics, spirometry, fitness level, allergy, and exhaled nitric oxide. We used multiple regression modeling to predict the annual decline in FEV1, reported as regression coefficients (R) and 95% confidence intervals (CIs). A total of 123 (43% of those invited) participated in the follow-up examination, where more had exercise-induced dyspnea but fewer had asthma symptoms. Being female (R = −29.8 ml, CI: −39.7 to −19.8), diagnosed with asthma (R = −13.7, CI: −20.4 to −7.0) or atopic dermatitis (R = −29.0, CI: −39.7 to −18.4), and having current asthma symptoms or nightly respiratory symptoms (R = −22.1, CI: −31.9 to −12.4 and R = −14.3, CI: −19.9 to −8.7, respectively) were significantly associated with a steeper decline in FEV1. Although to a smaller extent, a steeper decline was also predicted by age, baseline FEV1, waist/hip-ratio, and number of pack-years smoked. In individuals with preexisting AL, being female and having ever or current respiratory symptoms were associated with an accelerated annual decline in FEV1.

KW - Airflow limitation

KW - asthma

KW - chronic obstructive pulmonary disease

KW - lung function decline

KW - respiratory symptoms

U2 - 10.1177/1479973119838278

DO - 10.1177/1479973119838278

M3 - Journal article

C2 - 31159575

AN - SCOPUS:85066954694

VL - 16

JO - Chronic Respiratory Disease

JF - Chronic Respiratory Disease

SN - 1479-9723

ER -